Chromophobe renal cell cancer - Review of the literature and potential methods of treating metastatic disease

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Stec, Rafał ^a   Grala, Bartłomiej ^a   Ma̧cZewski, Michał ^b   Bodnar, Lubomir ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COLONY STIMULATING FACTOR 1 RECEPTOR; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 1; EPHRIN RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SORAFENIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VIMENTIN; ANTINEOPLASTIC AGENT;

CANCER INCIDENCE; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; FEMALE; KIDNEY TUMOR; MALE; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 70350340074     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-134     Document Type: Review

References (39)

1. Nowotwory zoliwe w Polsce w 2004 roku. U Wojciechowska J Didkowska W Tarnowski W Zatõski, Zachorowania na nowotwory zoliwe (stan na 30 czerwca 2006 roku); Warszawa 2006 94 101
2. Nowotwory ukadu moczowo-pciowego. M Pawlicki P Siedlecki, W: Onkologia Kliniczna. Maciej Krakowski (red.) Wydawnictwo Medyczne Borgis; Warszawa 2006 922 925
3. Tumors of The system and male genital organs. JN Eble G Sauter JI Epstein IA Sesterhenn, Lyon, France: IARC Press 2004
4. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. JC Cheville CM Lohse H Zincke H Weaver AL Blute L Michael, Am J Surg Pathol 2003 27 612 624 10.1097/00000478-200305000-00005 12717246 (Pubitemid 36514472)
5. Common and uncommon Histologic Subtype of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation. SR Prasad PA Humphrey R Jay Narra JR Srigley AD Cortez NC Dalrymple KN Chintapalli, Radiographics 2006 26 1795 1810 10.1148/rg.266065010 17102051
6. Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic prognostic Parameters in 145 Cases. MB Amin GP Paner Alvarado-Cabrero I Alvarado-Cabrero AN Young HJ Stricker RH Lyles H Moch, Am J Surg Pathol 2008 32 1822 1834 10.1097/PAS.0b013e3181831e68 18813125
7. Effect of Papillary and Chromophobe Cell Type on Disease-Free Survival After Nephrectomy for Renal Cell Carcinoma. SDW Beck I Manish IM Patel ME Snyder MW Kattan RJ Motzer VE Reuter P Russo, Ann of Surg Oncol; 2004 11 1 71 77 10.1007/BF02524349
8. Human chromophobe cell renal carcinoma. W Thoenes S Storkel MJ Rumpelt, Virchows Arch Cell Pathol 1985 48 207 217 10.1007/BF02890129
9. Chromophobe Renal Cell Carcinoma With Extensive Calcification and Ossification. SL Wu IJ Fishman RL Shanon, Ann of Diag Pathol 2002 6 4 244 247 10.1053/adpa.2002.34731 (Pubitemid 34894742)
10. Distribution of cytokeratins and Vimentin in adult renal neoplasms and normal renal tissue. BF Skinnider AL Flope RA Hennigar SD Lim C Cohen P Tomboli, Am J Surg pathol 2005 29 747 754 10.1097/01.pas.0000163362.78475.63 15897741
11. Parvalbumin is constantly expressed in Chromophobe Renal Carcinoma. G Martignoni M Pea M Chilosi M Brunelli A Scarpa C Colato R Tardanico G Zamboni F Bonetti, Mod Pathol 2001 14 8 760 767 10.1038/modpathol.3880386 11504835
12. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience. J-J Patard E Leray N Rioux-Leclercq L Cindolo V Ficarra A Zisman A De La Taille J Tostain W Artibani CC Abbou B Lobel F Guillé DK Chopin PFA Mulders CG Wood DA Swanson RA Figlin AS Belldegrun AJ Pantuck, J Clin Oncol 2005 23 12 2763 2771 10.1200/JCO.2005.07.055 15837991
13. Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: carcinoma retrospective analysis on computed tomography and magnetic resonance imaging studies. T Kondo H Nakazawa F Sakai K Tomo O Shiro H Yasunobu T Hiroshi, Int Urol 2004 11 817 824 10.1111/j.1442-2042. 2004.00907.x (Pubitemid 39490730)
14. Molecular genetics of familial renal cell carcinoma syndromes. D Cohen M Zhou, Clin Lab Med 2005 25 259 277 10.1016/j.cll.2005.01.003 15848736
15. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. MA Vira KR Novakovic PA Pinto WM Linehan, BJU Int 2007 99 1223 1229 10.1111/j.1464-410X.2007.06814.x 17441915
16. Application of molecular diagnostic techniques to renal epithelial neoplasms. TD Jones JN Eble L Cheng, Clin Lab Med 2005 25 279 303 10.1016/j.cll.2005.01.011 15848737
17. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinoma. A Kovacs S Storkel W Thoenes G Kovacs, J Pathol 1992 167 273 277 10.1002/path.1711670303 1381433
18. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. M Miettinen J Lasota, Appl Immunohistochem Mol Morphol 2005 13 3 205 220 10.1097/01.pai.0000173054.83414.22 16082245
19. Overexpression of KIT in chromophobe renal cell carcinoma. K Yamazaki M Sakamoto T Ohta Y Kanai M Ohki S Hirohashi, Oncogene 2003 22 847 852 10.1038/sj.onc.1206153 12584564
20. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. L Zhen-Hua H Eun Mee L Eung Seok W Kim Chul K Kim Han I Kim Y-S Kim, Modern Pathology 2004 17 611 616 10.1038/modpathol.3800108 15073597 (Pubitemid 38715481)
21. Expression of KIT (CD 117) in renal cell carcinoma and renal oncocytoma. S Krger K Sotlar I Kausch HP Horny, 2005 68 269 275
22. Overexpression of KIT (CD 117) in chromophobe renal cell carcinoma and renal oncocytoma. CC Pan CH Chen H Chiang, Am J Clin Pathol 2004 121 878 883 10.1309/A7M2XTMJQK0KPQER 15198361
23. Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]. MC Heinrich JS Shoemaker CL Corless D Hollis GD Demetri MM Bertagnolli JA Fletcher, J Clin Oncol 2005 23 16S 3s Abstract 7
24. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. O Hantschel U Rix G Superti-Furga, Leukemia & Lymphoma 2008 49 4 615 619 18398720
25. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. U Rix O Hantschel G Durnberger LL Remsing Rix M Planyavsky NV Fernbach I Kaupe KL Bennett P Valent J Colinge T Köcher G Superti-Furga, Blood 2007 110 5055 4063 10.1182/blood-2007-07-102061 (Pubitemid 350248462)
26. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. O'Hare DK Walters DP Stoffregen DW Sherbenou MC Heinrich MWN Deininger BJ Druker, Clin Cancer Res 2005 11 6987 6993 10.1158/1078-0432.CCR-05-0622 16203792
27. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. H Kantarijan R Pasquini N Hamerschlak P Rousselot J Holowiecki S Jootar T Robak N Khoroshko T Masszi A Skotnicki A Hellmann A Zaritsky A Golenkov J Radich T Hughes A Countouriotis N Shah, Blood 2007 109 5143 5150 10.1182/blood-2006-11- 056028 17317857 (Pubitemid 46890528)
28. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. E Wiesberg PW Manley W Breitenstein J Brüggen SW Cowan-Jacob A Ray B Huntly D Fabbro G Fendrich E Hall-Meyers AL Kung J Mestan GQ Daley L Callahan L Catley C Cavazza A Mohammed D Neuberg RD Wright DG Gilliland JD Griffin, Cancer Cell 2005 7 2 129 141 10.1016/j.ccr.2005.01.007 15710326
29. Nilotinib. MW Deininger, Clin Cancer Res 2008 14 13 10.1158/1078-0432. CCR-07-5015
30. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. N Brownlow AE Russell H Saravanapavan M Wiesmann JM Murray PW Manley NJ Dibb, Leukemia 2008 22 649 652 10.1038/sj.leu.2404944 17851554
31. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. E Weisberg PW Manley SW Cowan-Jacob A Hochhaus JD Griffin, Nature Reviews Cancer 2007 7 345 356 10.1038/nrc2126 17457302
32. AMN107, a Novel Aminopyrfimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. M Golemovic S Verstovsek F Giles J Cortes1 T Manshouri1 PW Manley J Mestan M Dugan L Alland JD Griffin RB Arlinghaus T Sun H Kantarjian M Beran, Cancer Res 2005 11 13 4941 4947 10.1158/1078-0432.CCR-04-2601 (Pubitemid 41557215)
33. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. HM Kantarjian F Giles N Gattermann K Bhalla G Alimena F Palandri GJ Ossenkoppele F-E Nicolini SG O'Brien M Litzow R Bhatia F Cervantes A Haque Y Shou DJ Resta A Weitzman A Hochhaus Coutre Philipp le, Blood 2007 110 10 3540 3546 10.1182/blood-2007-03-080689 17715389
34. Sunitynib versus interferon alfa in metastatic renal cell carcinoma. RJ Motzer TE Hudson P Tomczak D Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik STBS Kim I Chen PW Bycott CM Baum RA Figlin, N Eng J Med 2007 356 115 124 10.1056/NEJMoa065044 (Pubitemid 46089672)
35. Sorafenib in advanced renal-cell carcinoma. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TEDO Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski, N Eng J Med 2007 356 125 134 10.1056/NEJMoa060655 (Pubitemid 46089673)
36. In vivo antitumor activity of SU1 a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derive d growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss J Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington, Clin Cancer Res 1248 9 327 37
37. Efficacy of Sunitynib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. TK Choueiri A Plantade P Elson S Negrier A Ravaud S Oudard M Zhou BI Rini RM Bukowski B Escudier, J Clin Oncol 2008 26 1 127 131 10.1200/JCO.2007.13.3223 18165647
38. Renal-cell carcinoma. RJ Motzer NH Bander DM Nanus, N Eng J Med 1996 335 865 875 10.1056/NEJM199609193351207 (Pubitemid 26304070)
39. Serum levels of vascular endothelial growth factor VEGF) and endostatin in renal cell carcinoma patients compared to a control group. L Schips O Dalpiaz K Lipsky C Langner P Rehak P Puerstner K Pummer R Zigeuner, Eur Urol 2007 51 168 174 10.1016/j.eururo.2006.06.026 16844285